Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

Purpose As part of the American Association of Physicists in Medicine Working Group on
Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) …

Purpose This guideline provides updated evidence-based recommendations addressing
recent developments in the management of patients with brain metastases, including …

Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …

The management of patients with brain metastases has become a major issue due to the
increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014 …

Considerable interest is being directed toward combining immune-checkpoint inhibition (ICI)
with radiotherapy to improve response rates to ICI, which have been disappointingly low at …

The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …

Purpose Pembrolizumab is active in melanoma, but activity in patients with untreated brain
metastasis is less established. We present long-term follow-up of pembrolizumab-treated …

A recent meeting was held on March 22, 2019, among the FDA, clinical scientists,
pharmaceutical and biotech companies, clinical trials cooperative groups, and patient …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …